Obesity Medication & Costs: Weight Loss, Treatment & Rising Prices
- Recent developments are poised to significantly alter the landscape of obesity treatment, with new agreements aiming to lower the cost of popular weight loss medications.
- Trump announced agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk to reduce prices for widely used drugs like Ozempic, Wegovy, Zepbound, and Orforglipron.
- Currently, Ozempic and Wegovy list for $1,000 and $1,350 per month, respectively.
Recent developments are poised to significantly alter the landscape of obesity treatment, with new agreements aiming to lower the cost of popular weight loss medications. These changes come as interest in such drugs continues to rise, particularly among middle-aged and older adults.
Lowering Costs Through TrumpRx
On , President Donald J. Trump announced agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk to reduce prices for widely used drugs like Ozempic, Wegovy, Zepbound, and Orforglipron. The reductions will be available to patients purchasing through a new direct-to-consumer platform called TrumpRx, slated to launch in early . These agreements also extend to Medicare and Medicaid recipients.
Currently, Ozempic and Wegovy list for $1,000 and $1,350 per month, respectively. Through TrumpRx, these prices will fall to $350 per month. Zepbound and Orforglipron, if approved by the Food and Drug Administration (FDA), will be priced at an average of $346 per month through the same platform, down from a current list price of $1,086. Should oral formulations of Wegovy or similar GLP-1 drugs receive FDA approval, the initial dose will be available for $150 per month via TrumpRx.
Impact on Medicare and Medicaid
The price reductions negotiated by President Trump are expected to have a substantial impact on the affordability of obesity medications for those enrolled in Medicare and Medicaid. The Medicare price for Ozempic, Wegovy, Mounjaro, and Zepbound will be $245, which is less than half the price previously proposed by the Biden Administration. State Medicaid programs will also have access to these medications at the reduced rate.
This is particularly significant as these lower prices will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related health conditions for the first time. Previously, the cost of these medications presented a barrier to coverage.
GLP-1 Medications and Rising Popularity
GLP-1 medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro), have seen a surge in popularity in recent years. These drugs work by mimicking a natural hormone that regulates appetite and blood sugar, leading to weight loss. Approximately 12 percent of Americans, or around 40 million people, have used a GLP-1 medication for weight loss, with about one-fifth of women aged 50 to 64 being among those users, according to recent reports.
Interest in these medications is high, with 63 percent of adults aged 50 to 80 who are overweight expressing a desire to take a weight loss medication. However, the high cost of these drugs has been a significant barrier to access for many.
Concerns About Costs and Accessibility
Despite their growing popularity, the high list prices – often exceeding $1,000 per month – have made these medications difficult for many adults to afford. A recent report highlighted that affordability remains a major concern for those using GLP-1s. There are concerns about potential cost increases in related programs and services.
Recent reports indicate a potential for significant cost increases in lifestyle programs and medications for obesity. This underscores the importance of initiatives like the TrumpRx platform and the negotiated price reductions to ensure broader access to these treatments.
Looking Ahead
The implementation of TrumpRx in early will be a key factor in determining the extent to which these price reductions translate into increased access to obesity medications. The agreements with Eli Lilly and Novo Nordisk represent a significant step towards making these treatments more affordable for Americans, particularly those covered by Medicare and Medicaid. Continued monitoring of costs and accessibility will be crucial to ensure that these medications reach those who could benefit from them.
The potential for oral formulations of GLP-1 drugs to become available at a reduced price of $150 per month through TrumpRx also offers a promising avenue for expanding access. This could be particularly appealing to patients who prefer oral medications over injections.